We use cookies to see how investors use El Fondo and make its tools, data and markets better for you. You can accept or reject; essential cookies always stay on. Privacy Policy
Trades about 1% below its sector, cheaper than its peers on earnings.
Jiangsu Jibeier Pharmaceutical Co., Ltd. is a pharmaceutical enterprise based in Zhenjiang, China, established in 2001. The company's core operations involve the research, development, manufacturing, and sales of a diverse range of pharmaceutical products, including chemical preparations, traditional Chinese medicine formulations, and active pharmaceutical ingredients (APIs). Its product portfolio addresses various health concerns, offering solutions for boosting white blood cell counts, enhancing the immune system, treating joint-related ailments, managing high blood pressure, combating ocular infections, alleviating bronchitis symptoms, and protecting liver function, among others. Additionally, Jiangsu Jibeier is actively engaged in developing new therapeutic drugs, with its pipeline focusing on treatments for conditions such as depression, oncology (tumors), and gastrointestinal disorders.
Loading the full price history…
Run your own numbersPast performance is not a forecast.
Save 688566.SS and get told when something moves.
Get updates
A clear, direct weekly summary.
Learn the fundamentals behind this asset.
A stock is a fraction of ownership in a real company. Buy one share and you own a piece (usually a tiny piece) of every desk, factory, contract and brand the company runs. The price moves because the market keeps revising what that whole pie is worth.
The price-to-earnings ratio is how much investors are paying for one dollar of a company's profit. A multiple, never an absolute. Always compared to something: a sector, a region, the company's own past.
Dividend yield is the annual income a stock or ETF pays out, expressed as a percentage of what you paid for it. It is the visible part of total return: the cash that lands in your account every quarter, and the lever most retail investors actually feel.
Market cap is shares times price. A simple formula that produces wildly unequal numbers: a single US tech name can be worth more than every company on a LATAM exchange combined.
